最新消息

news

:::

蘇文彬 老師, Myeloid-derived suppressor cells-guided mesoporous silica nanoplatform delivering a BET inhibitor exerts anticancer effects by reprogramming the immunosuppressive tumor microenvironment., Chemical Engineering Journal, 2026, 543, 178042.

Abstract
Mivebresib (Miv), a pan-bromodomain and extra-terminal motif (BET) inhibitor currently in clinical trials for several solid tumors, including pancreatic ductal adenocarcinoma (PDAC), primarily exerts its antitumor activity through epigenetic regulation. However, its clinical potential is limited by poor solubility and bioavailability. Moreover, the tumor microenvironment (TME) is a major driver of therapeutic resistance in PDAC. Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) represent key therapeutic targets, the predominant immunosuppressive populations within the TME. To address these challenges, Miv was encapsulated into functionalized mesoporous silica nanoparticles (C8-RMSN), yielding Miv@C8-RMSN with uniform morphology, high loading efficiency, and excellent dispersibility. In vitro, this formulation preserved the pharmacological activity of Miv against PDAC cells and TAMs, while promoting M1 macrophage polarization via both tumor–macrophage interaction-dependent and macrophage-intrinsic mechanisms. In vivo, Miv@C8-RMSN demonstrated tumor accumulation, metabolic clearance, and favorable biosafety profiles, while achieving significant antitumor efficacy at an effective dose equivalent to 1/14 of the original dosing regimen (1 mg/kg/day oral Mivebresib administered for 14 consecutive days; total cumulative dose: 14 mg/kg). To further target MDSCs, H6-decorated Miv@C8-RMSN was developed, which enhanced cellular uptake and increased apoptosis-associated cytotoxicity in MDSCs. This system was associated with enhanced antitumor immune activation and induction of immunogenic cell death hallmarks, while achieving comparable therapeutic effects at a further reduced total dose (approximately 0.5 mg/kg Mivebresib), corresponding to an overall 1/28 dose reduction. Collectively, this MSN-based nanoplatform provides a promising immunotherapeutic strategy to potentiate BET inhibitor efficacy in PDAC by remodeling the immunosuppressive TME.

Keywords: Pancreatic ductal adenocarcinoma; Tumor microenvironment; Mesoporous silica nanoparticles; Mivebresib (ABBV-075); Myeloid-derived suppressor cells; Tumor-associated macrophages; Immunogenic cell death